NME1 and Parkinson disease: It is noteworthy that NME1 copy number reductions at the 3-prime end of NME1 gene have been reported in dementia with Lewy body (DLB) and that in PD, NME1 transcripts have been found to be reduced in comparison to controls (Kun-Rodrigues et al., 2019) [21]. This lends support to the proposal that NME1 is a potential candidate for therapeutic approaches to neurodegenerative disease.